Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX 3 CL1/CX 3 CR1 Pathway in Experimental Mouse Models of Systemic Sclerosis
To assess the preclinical efficacy and mechanism of action of an anti-CX CL1 monoclonal antibody (mAb) in systemic sclerosis (SSc). Cultured human dermal fibroblasts were used to evaluate the direct effect of anti-CX CL1 mAb on fibroblasts. In addition, bleomycin-induced and growth factor-induced mo...
Gespeichert in:
Veröffentlicht in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2019-11, Vol.71 (11), p.1923 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To assess the preclinical efficacy and mechanism of action of an anti-CX
CL1 monoclonal antibody (mAb) in systemic sclerosis (SSc).
Cultured human dermal fibroblasts were used to evaluate the direct effect of anti-CX
CL1 mAb on fibroblasts. In addition, bleomycin-induced and growth factor-induced models of SSc were used to investigate the effect of anti-CX
CL1 mAb on leukocyte infiltration, collagen deposition, and vascular damage in the skin.
Anti-CX
CL1 mAb treatment significantly inhibited Smad3 phosphorylation (P < 0.05) and expression of type I collagen and fibronectin 1 (P < 0.01) in dermal fibroblasts stimulated with transforming growth factor β1 (TGFβ1). In the bleomycin model, daily subcutaneous bleomycin injection increased serum CX
CL1 levels (P < 0.05) and augmented lesional CX
CL1 expression. Simultaneous administration of anti-CX
CL1 mAb or CX
CR1 deficiency significantly suppressed the dermal thickness, collagen content, and capillary loss caused by bleomycin (P < 0.05). Injection of bleomycin induced expression of pSmad3 and TGFβ1 in the skin, which was inhibited by anti-CX
CL1 mAb. Further, the dermal infiltration of CX
CR1+ cells, macrophages (inflammatory and alternatively activated [M2-like] subsets), and CD3+ cells significantly decreased following anti-CX
CL1 mAb therapy (P < 0.05), as did the enhanced skin expression of fibrogenic molecules, such as thymic stromal lymphopoietin and secreted phosphoprotein 1 (P < 0.05). However, the treatment did not significantly reduce established skin fibrosis. In the second model, simultaneous anti-mCX
CL1 mAb therapy significantly diminished the skin fibrosis induced by serial subcutaneous injection of TGFβ and connective tissue growth factor (P < 0.01).
Anti-CX
CL1 mAb therapy may be a novel approach for treating early skin fibrosis in inflammation-driven fibrotic skin disorders such as SSc. |
---|---|
ISSN: | 2326-5205 |
DOI: | 10.1002/art.41009 |